272 related articles for article (PubMed ID: 21321086)
1. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
Blumenschein GR; Kabbinavar F; Menon H; Mok TSK; Stephenson J; Beck JT; Lakshmaiah K; Reckamp K; Hei YJ; Kracht K; Sun YN; Sikorski R; Schwartzberg L;
Ann Oncol; 2011 Sep; 22(9):2057-2067. PubMed ID: 21321086
[TBL] [Abstract][Full Text] [Related]
2. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR
J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922
[TBL] [Abstract][Full Text] [Related]
3. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
Kubota K; Ichinose Y; Scagliotti G; Spigel D; Kim JH; Shinkai T; Takeda K; Kim SW; Hsia TC; Li RK; Tiangco BJ; Yau S; Lim WT; Yao B; Hei YJ; Park K
Ann Oncol; 2014 Feb; 25(2):529-36. PubMed ID: 24419239
[TBL] [Abstract][Full Text] [Related]
4. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K
J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534
[TBL] [Abstract][Full Text] [Related]
5. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Novello S; Scagliotti GV; Sydorenko O; Vynnychenko I; Volovat C; Schneider CP; Blackhall F; McCoy S; Hei YJ; Spigel DR
J Thorac Oncol; 2014 Aug; 9(8):1154-61. PubMed ID: 25157768
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Blumenschein GR; Reckamp K; Stephenson GJ; O'Rourke T; Gladish G; McGreivy J; Sun YN; Ye Y; Parson M; Sandler A
Clin Cancer Res; 2010 Jan; 16(1):279-90. PubMed ID: 20028752
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
8. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.
Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ
J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer.
De Boer RH; Kotasek D; White S; Koczwara B; Mainwaring P; Chan A; Melara R; Ye Y; Adewoye AH; Sikorski R; Kaufman PA
Breast Cancer Res Treat; 2012 Aug; 135(1):241-52. PubMed ID: 22872523
[TBL] [Abstract][Full Text] [Related]
10. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
11. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
12. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Socinski MA; Garon EB; Reynolds CH; Spigel DR; Olsen MR; Hermann RC; Jotte RM; Beck T; Richards DA; Guba SC; Liu J; Frimodt-Moller B; John WJ; Obasaju CK; Pennella EJ; Bonomi P; Govindan R
J Clin Oncol; 2013 Dec; 31(34):4349-57. PubMed ID: 24145346
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.
Hong DS; Kurzrock R; Mulay M; Rasmussen E; Wu BM; Bass MB; Zhong ZD; Friberg G; Rosen LS
Oncotarget; 2014 Nov; 5(22):11154-67. PubMed ID: 25525888
[TBL] [Abstract][Full Text] [Related]
16. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
[TBL] [Abstract][Full Text] [Related]
17. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Spigel DR; Patel JD; Reynolds CH; Garon EB; Hermann RC; Govindan R; Olsen MR; Winfree KB; Chen J; Liu J; Guba SC; Socinski MA; Bonomi P
J Thorac Oncol; 2015 Feb; 10(2):353-9. PubMed ID: 25611228
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.
Dingemans AM; Groen HJ; Herder GJ; Stigt JA; Smit EF; Bahce I; Burgers JA; van den Borne BE; Biesma B; Vincent A; van der Noort V; Aerts JG;
Ann Oncol; 2015 Nov; 26(11):2286-93. PubMed ID: 26347109
[TBL] [Abstract][Full Text] [Related]
19. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Marrone KA; Zhou X; Forde PM; Purtell M; Brahmer JR; Hann CL; Kelly RJ; Coleman B; Gabrielson E; Rosner GL; Ettinger DS
Oncologist; 2018 Jul; 23(7):859-865. PubMed ID: 29487223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
